论文信息 - Is itching in atopic dermatitis still an unmet need? A case series of 556 patients

Is itching in atopic dermatitis still an unmet need? A case series of 556 patients

Data availability statement The data that support the findings of this study are available from the Department of Dermatology, University Hospital Leipzig, Germany. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from L B€ ohler, K Dumann, M Kunz/lisa.boehler@medizin.unileipzig.de with the permission of the Department of Dermatology, University Hospital Leipzig, Germany.

[1] G. Argenziano,et al. Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2] G. Argenziano,et al. Dual Efficacy of Upadacitinib in 2 Patients With Concomitant Severe Atopic Dermatitis and Alopecia Areata. , 2021, Dermatitis.

[3] J. Paolini,et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin‐31, oncostatin M, IL‐31 receptor alpha and oncostatin M receptor beta , 2021, Experimental dermatology.

[4] R. Tanei. Atopic Dermatitis in Older Adults: A Review of Treatment Options , 2020, Drugs & Aging.

[5] A. Murphy,et al. Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation , 2019, Allergy.

[6] K. Kabashima,et al. Interleukin‐31 and interleukin‐31 receptor: New therapeutic targets for atopic dermatitis , 2018, Experimental dermatology.